Ernexa Therapeutics

Ernexa Therapeutics Inc.

15 Investors

Cell Therapy, Biotechnology

CAMBRIDGE, MA

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell therapy solutions for advanced cancer and autoimmune diseases. They use induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) with unique targeting capabilities, enabling the creation of scalable, off-the-shelf therapies. This method eliminates the need for patient-specific solutions.

Products & Team

ERNA-101

Cell TherapySeed

ERNA-101 is a cell therapy product in development for the treatment of ovarian cancer. It leverages the natural tumor-homing abilities of iMSCs to deliver pro-inflammatory cytokines like IL-7 and IL-15 directly to the tumor microenvironment, enhancing the immune system's ability to target and destroy cancer cells.

Value Proposition

Offers a novel and targeted therapeutic option for ovarian cancer with limited systemic side effects by delivering pro-inflammatory cytokines directly to the tumor. This approach aims to improve the immune system's ability to recognize and eliminate cancer cells.

Pain Points

Lack of effective targeted therapies and resistance to platinum-based chemotherapy.

iMSC-based cell therapyTumor-homing capabilitiesTargeted delivery of pro-inflammatory cytokinesEnhanced immune response against cancer cells